MassBio’s 2018 Industry Snapshot – Boston/Cambridge Leads the Way

Introduction of press release from MassBio: "August 29 - The Massachusetts Biotechnology Council (MassBio) released its 2018 Industry Snapshot report, which shows that Massachusetts biotechs dominated the IPO market in 2017, accounting for nearly half of all US-based biotech IPOs (48%), up from 30% in 2016. 2018 has already outpaced 2017 in terms of total Massachusetts IPOs [...]

September 3rd, 2018|

Spotlight: First Coast Tech Hubs Gather @ RESI Boston

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series The First Coast Innovator’s Gathering is a new component of the Redefining Early Stage Investments (RESI) Conference Series which was requested by the investors and strategic channel partners who routinely attend RESI. Many of these partners wanted LSN to bring the “earliest stage” [...]

August 23rd, 2018|

May Financial Focus: Boston Area a Hot-Bed for Biopharma Startups

By Marie Daghlian VC funding for Boston area biotech companies is on fire and its momentum shows no signs of slowing up. Boston area biotech and health-related companies raised $1.58 billion in 32 deals in the first quarter of 2018. That compares favorably with the $1.59 billion raised in Q4 2017 in 42 deals, and [...]

May 14th, 2018|

Latest Startup From Harvard’s Springer Gets $51.5M

From press release: "Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs, announced today that it has completed a $51.5 million Series A financing to advance multiple programs into the clinic. The round was co-led by SR One and Pfizer Venture Investments, joined by Omega Funds and AbbVie Ventures. They join [...]

June 30th, 2016|

Medtronic to Acquire HeartWare in $1.1B Deal

Intro of HeartWare press release: "Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire HeartWare in [...]

June 27th, 2016|

Life In The Trenches Of A Biotech LLC

Jeb Keiper, CBO of Nimbus Therapeutics LLC, has written a great blogpost (as part of the "From The Trenches" feature of LifeSciVC) about corporate financing, program-focused subsidiaries, the differences between "inc." and "llc", and much more. The intro: "Unsurprisingly, I had not given that much thought to the parent entity of my new employer when [...]

June 21st, 2016|

How to Pay for Cutting-Edge Drugs?

In the feature "Promising gene therapies pose million-dollar conundrum," Erika Check Hayden/Nature details how stakeholders in various segments of the life sciences and healthcare are trying to wrangle through the financial/pricing knots of gene therapies. The intro: "Drugs that act by modifying a patient’s genes are close to approval in the United States, and one is already available in [...]

June 15th, 2016|

Vedanta Nabs $50M

Coverage on PureTech's microbiome biotech, Vedanta Biosciences, raising $50M: "Exploration of the human microbiome has spurred countless questions about the impact the trillions of microbes in and on our bodies have on our health. Those questions have led to a growing number of new biotech companies. One of the first to launch, Vedanta Biosciences of Cambridge, MA, has [...]

June 6th, 2016|

Why Sarepta’s Shares Slumped

From Dan Caplinger/Motley Fool: "Sarepta Therapeutics plunged 27% after the Food and Drug Administration released information that could threaten the company's ability to maximize profits if its treatment for Duchenne muscular dystrophy eventually receives FDA approval. The FDA's recommendations centered on its compassionate use policy, saying companies generally could only get paid to offset its [...]

June 2nd, 2016|

Celgene, Agios in $1B+ Metabolic Immuno-Oncology Alliance

Excerpts of coverage: Bloomberg Bay State Biotech Report: Celgene’s New Agios Cancer Drug Deal: GEN - "Celgene and Agios Pharmaceuticals will partner to develop metabolic immuno-oncology therapies, under a strategic alliance that could generate about $1 billion-plus for Agios.The companies said they will discover, develop, and commercialize new treatments focused on altering the [...]

May 18th, 2016|